<DOC>
	<DOC>NCT00418522</DOC>
	<brief_summary>This study is to determine if inhaled insulin is effective in treating type 2 diabetes mellitus.</brief_summary>
	<brief_title>This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Age &gt; 30 years and â‰¤ 75 years with a diagnosis of type 2 diabetes mellitus made &gt; 6 months prior to study entry Screening HbA1c &gt; 7.0% Currently treated on a stable dose of at least 2 oral antidiabetic agents for at least 3 months prior to study entry; including a sulfonylurea and/or metformin, and/or a thiazolidinedione Smoking within last 6 months PFTs outside of range Type 1 diabetes mellitus Type 2 diabetes mellitus currently (last three months) treated with an insulin regimen (alone or with Oral Antidiabetic Agents) Active liver disease; significantlyimpaired hepatic function, as shown by, but not limited to, alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) or aspartate transaminase (AST) serum glutamicoxaloacetic transaminase (SGOT) above 2x the upper limit of normal as measured at visit 1. However, patients with elevated ALT &gt;1.5 upper limit of normal as a result of hepatic steatosis are permitted to enter the study.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Insulin Glargine Diabetes HbA1c</keyword>
</DOC>